Steve Gillis, Ph.D.
Dr. Steven Gillis is a managing director with ARCH Venture Partners, joining the firm in 2005. Dr. Gillis is focused on the evaluation of new life science technologies and also on the development and growth of ARCH’s biotechnology portfolio companies. He is a director of Accelerator, Allozyne, Variation Biotechnologies, Surface Logix, PhaseRx, Pulmatrix and Qwell Pharmaceuticals. He serves as director and chairman of VentiRx Pharmaceuticals, Spaltudaq and VLST. As a former director and chairman of Trubion Pharmaceuticals (TRBN), he led its acquisition by Emergent BioSolutions in early 2010.
Dr. Gillis was a founder and director of Corixa Corp. and served as the company’s chief executive officer from its inception and as its chairman from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was a founder and director of Immunex Corp. From 1981 until his departure in 1994, he served as Immunex’s director of research and development, chief scientific officer, and as chief executive officer of Immunex’s R&D subsidiary. Dr. Gillis was interim chief executive officer of Immunex Corp. following its majority purchase by American Cyanamid Co. and remained a member of the board until 1997. Amgen, Inc. acquired Immunex in 2002.
Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein), as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Dr. Gillis received a B.A. from Williams College and a Ph.D. from Dartmouth College.
Kristina Burow is a Managing Director with ARCH Venture Partners and is focused on the creation and development of biotechnology, pharmaceutical and agbiotechnology companies. Since joining ARCH in 2002 Ms. Burow has played a significant role in the creation and development of a number of companies. Ms. Burow is a Director of Vividion Therapeutics, Lycera, BlackThorn Therapeutics, Sienna Biopharmaceuticals, Metacrine, Scholar Rock, Unity Biotechnology, AgBiome, AgTech Accelerator and Vir Biotechnology. She previously was a co-founder and Director of Receptos (RCPT – acquired by Celgene). Ms. Burow has participated in a number of other ARCH portfolio companies including Siluria Technologies, Kythera (KYTH – acquired by Allergan), Ikaria (acquired by Madison Dearborn) and was a co-founder and board member of Sapphire Energy. Prior to joining ARCH Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development where she helped create numerous companies as spin-outs from GNF. Ms. Burow holds a M.B.A. from the University of Chicago, a M.A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.
Pablo Cagnoni, MD
Dr. Cagnoni is the President and CEO of Tizona Therapeutics, an immunology company that is harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases.
Over of the course of his career, Dr. Cagnoni has played a key role in the development, approval and/or commercialization of several life-changing medicines, including Afinitor®, Blincyto® Exjade®, Folotyn® Glivec®, Jakavi®, Kyprolis®, Signifor®, Tarceva®, Tasigna® and Zykadia® among them.
Most recently, he served as President of Onyx Pharmaceuticals where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. At the time of his departure, Onyx was on track to deliver yearly revenues in excess of $1B and had over 800 employees. Dr. Cagnoni joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology, where he was responsible for all clinical development, clinical operations, clinical pharmacology and correlative sciences activities for the oncology development pipeline. From 2007 to 2009, Dr. Cagnoni was Senior Vice President and Chief Medical Officer at Allos Therapeutics, and prior to that Chief Medical Officer of OSI Pharmaceuticals. Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program where he cared for patients undergoing stem cell transplants.
Dr. Cagnoni earned his medical degree from the University Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology at The Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.
Dr. Cagnoni is also on the board of directors of Harpoon Therapeutics and CRISPR Therapeutics.
Mary Lincoln Campbell
Mary Lincoln Campbell, Managing Director and Founder of EDF Ventures, has been an active investor both in healthcare and technology companies. Currently, Mary is a board member or board observer for: Cerenis Therapeutics and Lycera (pharmaceuticals); IntelePeer (telecommunications); ValenTx (medical devices); Arxan (software); and Accio Energy (wind-energy).
Mary led several of the firm’s most successful transactions including HandyLab, a developer of molecular diagnostic assays and automation platforms, sold to Becton Dickinson & Company; Sircon, a provider of automation solutions for the insurance industry, sold to Vertafore, the nation’s number one insurance software provider; and Greenplum, a database clustering software for business intelligence and data warehousing, sold to EMC Corporation, the world’s leading provider of information infrastructure solutions.
She is active with The Stephen M. Ross School of Business at The University of Michigan and serves as an advisor to the Zell Lurie Institute for Entrepreneurial Studies, as well as its student-run venture activity, the Wolverine Venture Fund. She serves on the advisory board of The Charles F. Dolan School of Business at Fairfield University. Mary is past president of the Michigan Venture Capital Association, the State’s premier public policy advocate for the venture capital industry.
Mary received her MBA and BA in English from The University of Michigan and a Master of Special Education from Fairfield University.
Robert Kamen, Ph.D.
Dr. Robert Kamen is a consultant to the biotech and pharmaceutical industry. Most recently, he was president of Abbott Bioresearch Center, Abbott Laboratories’ immunology drug discovery and biologics production unit in Worcester, Massachusetts, and a member of the Abbott Pharmaceuticals Executive Management Committee. During Dr. Kamen’s leadership at BASF/Abbott, the company established the technology platform for Humira™ (adalimumab), the first fully human antibody to achieve marketing approval in the U.S. (and Europe). Currently marketed for rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and psoriasis, Humira was the most rapidly growing U.S. biological drug in 2007 and 2008. In 2005, Dr. Kamen co-founded BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases, where he serves as chairman. In addition, Dr. Kamen is a member of several other biopharmaceutical company boards.
Dr. Kamen has an undergraduate degree in biophysics from Amherst College and a Ph.D. in biochemistry and molecular biology from Harvard University.
Nicholas J. Simon, MBA
Nicholas Simon has served as managing director of Clarus Ventures since the firm’s inception in 2005. Previously, Mr. Simon was general partner at MPM Capital. He has over 20 years of operating and investment experience in the biopharmaceutical industry, including at Genentech from 1989 to 2000, where he was vice president of business and corporate development.
Mr. Simon also represents Clarus Ventures on the Board of Directors of Gritstone Oncology, Nuvelution Pharma, Inc. and Sientra, where he serves as Lead Director. In addition, he is a member of the Foundation Board at the Gladstone Institute, a private not-for-profit research institute affiliated with the University of California, San Francisco.
Mr. Simon received his BS degree in microbiology from the University of Maryland and MBA from Loyola University.
Doug Fisher, MD
Doug joined InterWest’s healthcare team in 2009, focusing on biopharmaceutical, diagnostic and medical device investments, and portfolio company support. In addition to Lycera, Doug is a board member of Gynesonics, Indi Molecular, and Obalon Therapeutics (OBLN). Doug is also actively involved in InterWest’s investments in Integrated Diagnostics, PMV Pharma, Potenza Theraputics, Sera Prognostics (where he serves as the Chief Business Officer), Tizona Therapeutics, and Trieza Therapeutics.
Prior to joining InterWest, Doug was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including Pearl Therapeutics, Interlace Medical (Acquired by Hologic), and Stromedix (Acquired by Biogen Idec). Prior to joining New Leaf, Doug was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area, consulting for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group.
Doug received an A.B. in economics with honors and distinction, and a B.S. in biology with distinction, from Stanford, where he graduated Phi Beta Kappa. He has an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from Wharton, where he graduated with honors as a Siebel Scholar and Palmer Scholar.